Michael Polansky Unveils AI Biotech Startup Training Models on Living Human Skin Tissue

Key facts

According to reporting by TechCrunch, Michael Polansky spent years operating in stealth mode to build a platform that bridges functional tissue engineering and computational biology. Standard laboratory research in dermatology generally relies on two-dimensional cellular monolayers or basic three-dimensional skin models. However, standard isolated cell lines fail to capture the multi-layered dynamic behavior of human skin, while traditional ex vivo skin explants tend to suffer rapid degradation, typically breaking down within three to seven days of surgical removal.

Polansky's enterprise addresses this temporal constraint by developing specialized culture systems capable of extending the lifespan of full-thickness human skin tissue outside the human body for up to several weeks. The living tissue is typically sourced from consented surgical procedures, preserving the complex biological structure of the epidermis, dermis, and functional cellular interactions.

While the skin tissue remains viable in the laboratory, high-throughput automated instruments observe its metabolic, transcriptomic, and structural reactions to various chemical formulations. Specialized sensors track barrier integrity, inflammatory markers, matrix protein synthesis, and cellular stress in real time.

The high-density physiological datasets generated from these living samples are then fed directly into machine learning architectures. These AI models learn the biological relationships between chemical molecular structures and skin responses, enabling the software to simulate, predict, and optimize compound efficacy and safety prior to physical testing. This integrated feedback loop between living biological tissue and computational algorithms allows researchers to rapidly screen thousands of candidate molecules for anti-aging, hydration, anti-inflammatory, and therapeutic properties.

Why it matters

The convergence of extended-viability tissue culture and machine learning carries direct implications for global consumer cosmetics, clinical dermatology, and regulatory frameworks governing safety testing.

For the skincare and personal care industry—a global market evaluated at over $150 billion annually—product innovation has long been hindered by the limitations of early-stage testing. Many active ingredients in modern cosmetic formulations rely on compounds developed decades ago due to the high costs, length, and unpredictability of human clinical trials. By providing an ex vivo screening environment that accurately mimics living human skin over multi-week periods, Polansky's platform allows formulation scientists to identify promising molecules with higher predictive validity before committing to costly human trials.

From a regulatory and ethical perspective, the technology aligns with worldwide policy shifts away from animal testing. The European Union fully prohibited animal testing for cosmetic products and ingredients under Regulation (EC) No 1223/2009 in 2013. In the United States, Congress enacted the FDA Modernization Act 2.0 in late 2022, which formally permitted drug developers to use non-animal testing methods, including organ-on-a-chip and human tissue models, to demonstrate drug safety and efficacy. Extending the viable window of real human skin tissue gives researchers a physiologically accurate human system that reduces reliance on animal models, whose skin mechanics and immune responses differ substantially from those of humans.

In medical dermatology, chronic skin conditions such as eczema, psoriasis, rosacea, and severe burn reconstruction require therapies that target long-term tissue remodeling. Standard short-lived lab tissue models cannot survive long enough to observe cellular turnover or multi-week therapeutic responses. A platform that maintains living tissue for weeks allows pharmaceutical researchers to evaluate drug candidates for complex skin diseases under controlled, observable laboratory conditions.

Michael Polansky's career has operated at the intersection of technology, venture finance, and medical innovation. For over a decade, Polansky served as a top lieutenant to Sean Parker, the co-founder of Napster and founding president of Facebook. As executive director of the Parker Foundation and managing director of the Parker Group, Polansky oversaw large-scale philanthropic and venture efforts. In 2016, he played a central role in launching the Parker Institute for Cancer Immunotherapy, backed by a $250 million commitment from Parker, which brought together prominent cancer research institutions to accelerate breakthrough immunotherapies.

Beyond his institutional career, Polansky has attained public visibility as the partner of recording artist and entrepreneur Lady Gaga, with whom he co-founded the Born This Way Foundation's advisory efforts and coordinated major public health fundraising initiatives, including the 2020 One World: Together At Home broadcast during the COVID-19 pandemic.

The field of ex vivo tissue engineering has historically wrestled with the challenge of tissue preservation. When human skin is excised, the severance of blood supply quickly triggers cellular hypoxia, apoptosis, and structural breakdown. Standard tissue culture media can sustain outer epidermal layers briefly, but maintaining the dermal matrix, vascular endothelial structures, and resident immune cells requires continuous nutrient perfusion, controlled oxygenation, and precise mechanical conditions.

Simultaneously, the rise of AI-driven drug discovery has transformed biotechnology over the past decade. Companies such as Recursion Pharmaceuticals, Insitro, and Evolutionary Scale have demonstrated that biological automation paired with high-dimensional data generation can train machine learning models to predict molecular behavior. Applying this methodology specifically to full-thickness living skin represents an evolution toward tissue-specific foundation models in biological computation.

Reaction

The disclosure of Polansky's venture has generated widespread interest across both the technology investment community and personal care research sectors. While the company has maintained a low public profile regarding specific commercial clients, industry observers expect significant interest from major international cosmetic conglomerates and specialty pharmaceutical firms seeking advanced ingredient screening tools.

Bioethics scholars and regulatory specialists emphasize that ex vivo human tissue research must operate under strict ethical standards. Sourced surgical explants require informed donor consent, institutional review board approval, and rigorous anonymization to ensure compliance with human tissue research guidelines. Regulatory health agencies, including the U.S. Food and Drug Administration and the European Chemicals Agency, continue to refine guidelines for validating machine learning tools and non-animal tissue platforms in safety determinations.

What we don't know yet

Despite the details revealed in initial reports, several core operational and scientific metrics remain undisclosed. The startup's formal corporate title, total equity capital raised, valuation, and table of institutional venture backers have not been made public.

On the technical front, the specific biomechanical and chemical formulations used to maintain living skin tissue viability for multiple weeks without tissue degradation or bacterial contamination have not been published in peer-reviewed scientific journals. It remains uncertain how closely ex vivo skin cultures can simulate systemic biological responses, such as circulatory interaction, hormonal fluctuations, or neural signaling, over extended periods.

Furthermore, the business model of the venture remains partially unconfirmed. It is not yet clear whether the company intends to operate primarily as a contract research and discovery platform for corporate partners, license its proprietary AI-discovered compounds directly to cosmetic brands, or launch its own consumer-facing skincare products.

What to watch

In the coming months, several indicators will clarify the commercial and scientific trajectory of Polansky's startup.

First, researchers and industry analysts will watch for peer-reviewed studies published in dermatological or biomedical engineering journals, which would provide independent validation of the multi-week tissue survival rates and the predictive accuracy of the AI models.

Second, potential commercial announcements, including research partnerships or joint venture agreements with global personal care corporations or dermatological drug developers, will signal commercial adoption.

Third, patent disclosures filed with regulatory bodies such as the U.S. Patent and Trademark Office will offer visibility into the platform's proprietary culture mechanisms, sensor integration, and discovered chemical entities. Finally, any formal regulatory validation filings submitted to bodies like the FDA or European authorities will demonstrate the technology's readiness for formal safety testing applications.

This account is based on original reporting published by TechCrunch.